In mouse models of AD, the observed effects of triple-receptor agonists were anti-apoptotic effects, reduced Aβ deposition and hyperphosphorylated hippocampal tau, protection from loss of synapses, and reduced inflammatory and oxidative stress [308,309,310]. The gene discussed is MAPT; the disease is Alzheimer disease.